

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

PerCP/Cyanine5.5 anti-human CD8

RRID:AB_2044010

Type: Antibody

Proper Citation

BioLegend Cat# 344710, RRID:AB_2044010

Antibody Information

URL: http://antibodyregistry.org/AB_2044010

Proper Citation: BioLegend Cat# 344710, RRID:AB_2044010

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2044010

Vendor: BioLegend

Catalog Number: 344710

Alternative Catalog Numbers: 344709

Record Creation Time: 20250820T003100+0000

Record Last Update: 20250820T082836+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD8.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chi H, et al. (2025) SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint That Enables Tumor Immune Evasion by Impairing T-cell Cytotoxicity. Cancer research, 85(5), 912.

Huang F, et al. (2025) Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer cell, 43(8), 1460.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. Frontiers in immunology, 16, 1609658.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Forconi CS, et al. (2025) T-follicular helper cell profiles differ by malaria antigen and for children compared to adults. eLife, 13.

Forconi CS, et al. (2025) T follicular helper cell profiles differ by malaria antigen and for children compared to adults. bioRxiv : the preprint server for biology.

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. Cell reports. Medicine, 6(8), 102252.

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. Cell reports. Medicine, 6(12), 102466.

Shin OS, et al. (2024) Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38. Cell reports, 43(7), 114502.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell reports. Medicine, 5(6), 101585.

Rubino V, et al. (2024) IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. *Cell reports. Medicine*, 5(11), 101826.

Liu W, et al. (2024) An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. *Cell reports. Medicine*, 5(3), 101448.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Pai JA, et al. (2023) Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. *Cancer cell*, 41(4), 776.

Gfeller D, et al. (2023) Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. *Cell systems*, 14(1), 72.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Chow A, et al. (2023) The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. *Immunity*, 56(1), 93.

Hong J, et al. (2023) Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection. *Cell reports. Medicine*, 4(11), 101296.

Sacramento LA, et al. (2023) CCR5 promotes the migration of CD8+ T cells to the leishmanial lesions. *bioRxiv : the preprint server for biology*.